scholarly journals Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD

Biomolecules ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 1903
Author(s):  
Adrian Martyniak ◽  
Aleksandra Medyńska-Przęczek ◽  
Andrzej Wędrychowicz ◽  
Szymon Skoczeń ◽  
Przemysław J. Tomasik
Keyword(s):  
Intestinal Microbiota ◽  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Immunological Response ◽  
Bacterial Metabolism ◽  
Dietary Fibers ◽  
Beneficial Bacteria ◽  
New Methods ◽  
Bowel Diseases ◽  
Inflammatory Bowel

The increasing incidence of inflammatory bowel diseases (IBD) and the increasing severity of the course of these diseases create the need for developing new methods of therapy. The gut microbiome is extensively studied as a factor influencing the development and course of IBD. The composition of intestinal microbiota can be relatively easily modified by diet (i.e., prebiotics, mainly dietary fibers) and bacterial supplementation using beneficial bacteria strains called probiotics. Additionally, the effects of the improved microbiome could be enhanced or gained by using paraprobiotics (non-viable, inactivated bacteria or their components) and/or postbiotics (products of bacterial metabolism or equal synthetic products that beneficially modulate immunological response and inflammation). This study summarizes the recent works on prebiotics, probiotics, synbiotics (products merging pre- and probiotics), paraprobiotics and postbiotics in IBD.

scholarly journals Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences

2019 ◽  
Vol 7 (8) ◽  
pp. 1008-1032 ◽  
Author(s):  
Fatouma Salem ◽  
Nadège Kindt ◽  
Julian R Marchesi ◽  
Patrick Netter ◽  
Anthony Lopez ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Similarities And Differences

Protective effects of a novel probiotic strain, Lactococcus lactis ML2018, in colitis: in vivo and in vitro evidence

2019 ◽  
Vol 10 (2) ◽  
pp. 1132-1145 ◽  
Author(s):  
Meiling Liu ◽  
Xiuxia Zhang ◽  
Yunpeng Hao ◽  
Jinhua Ding ◽  
Jing Shen ◽  
...  
Keyword(s):  
Immune Responses ◽  
Lactococcus Lactis ◽  
Intestinal Microbiota ◽  
Inflammatory Bowel Diseases ◽  
Probiotic Strain ◽  
Protective Effects ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Multiple articles have confirmed that an imbalance of the intestinal microbiota is closely related to aberrant immune responses of the intestines and to the pathogenesis of inflammatory bowel diseases (IBDs).

scholarly journals Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases

2017 ◽  
Vol 21 (5) ◽  
pp. 603-610.e3 ◽  
Author(s):  
Ashwin N. Ananthakrishnan ◽  
Chengwei Luo ◽  
Vijay Yajnik ◽  
Hamed Khalili ◽  
John J. Garber ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Biologic Therapy ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Immunotherapeutic Effects of β-D Mannuronic Acid on IL-4, GATA3, IL-17 and RORC Gene Expression in the PBMC of Patients with Inflammatory Bowel Diseases

2018 ◽  
Author(s):  
Hussaini Alhassan Mohammed ◽  
Ali Akbar Saboor-Yaraghi ◽  
Homayoun Vahedi ◽  
Ghordratollah Panahi ◽  
Gholamreza Hemmasi ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Immunological Response ◽  
Quantitative Real Time Pcr ◽  
Mannuronic Acid ◽  
Immune Mediated ◽  
Genes Expression ◽  
Bowel Diseases ◽  
Research Findings ◽  
Inflammatory Bowel ◽  
Normal Controls

Inflammatory bowel diseases (IBD) are chronic relapsing immune-mediated disorders that result from an aberrant immunological response. IBD comprises of Crohn's disease (CD) and ulcerative colitis (UC). The precise aetiology of IBD has not been fully understood, however, recent studies support the hypothesis that patients with IBD have a dysregulated immune response to endogenous bacteria in the gastrointestinal tract (GIT). The increasing number of hospitalisation coupled with the high economic burden faced by IBD patients, calls for more concerted research efforts, to design a potent and credible treatment option for these strata of patients. This research was designed to test the efficacy and potency of β-D Mannuronic acid (M2000) in the treatment of IBD. Ten ml of blood was aseptically collected from 24 IBD patients and 24 normal controls. PBMC was isolated and stimulated with 1 µg/mL of LPS and incubated for 4 hours. The cells were later treated with 10 µg/mL or 50 µg/mL of Mannuronic acid and incubated for 24 hours at 370C under 5% CO2 and 100% humidity. After the incubation, RNA was extracted from the cells, cDNA was synthesised, and the expression of the gene was evaluated using quantitative real-time PCR. The result indicated a significant down-regulation of RORC and IL-17 genes expression, while the expression of IL-4 and GATA3 genes were significantly up-regulated. These research findings have shown that M2000 a biocompatible agent, that has an immunotherapeutic, immunomodulatory and immunosuppressive effects on the PBMC of IBD patients.

scholarly journals Intestinal microbiota and inflammatory bowel diseases

2021 ◽  
Vol 64 (9) ◽  
pp. 588-595
Author(s):  
Chang Soo Eun
Keyword(s):  
Intestinal Microbiota ◽  
Inflammatory Bowel Diseases ◽  
Intestinal Inflammation ◽  
Microbial Composition ◽  
Mucosal Permeability ◽  
Next Generation Sequencing Technology ◽  
Early Results ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
And Function

Background: The prevalence of inflammatory bowel diseases (IBD) has been rapidly increasing over the past several decades in Korea. IBD appears to be resulted from inappropriate and chronic activation of the mucosal immune system driven by stimuli such as intestinal microbiota and various environmental factors in genetically susceptible individuals.Current Concepts: Recent advances in next-generation sequencing technology have identified alterations in the composition and function of the intestinal microbiota in individuals with IBD. Dysbiosis in patients with IBD is characterized by decreased bacterial diversity combined with an expansion of putative aggressive species and a reduction in protective species. Altered microbial composition and function in IBD correlates with increased immune stimulation, epithelial dysfunction, or enhanced mucosal permeability. Thus, dysbiosis may play an essential role in the pathogenesis of IBD.Discussion and Conclusion: Although it is currently unclear whether dysbiosis is a cause or consequence of intestinal inflammation in IBD, several microbial-based and microbial-targeted therapies have yielded promising early results.

scholarly journals Metagenomic alterations in gut microbiota precede and predict onset of colitis in the IL10 gene-deficient murine model

2020 ◽  
Author(s):  
Jun Miyoshi ◽  
Sonny T. M. Lee ◽  
Megan Kennedy ◽  
Mora Puertolas ◽  
Mary Frith ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Clinical Outcomes ◽  
Murine Model ◽  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Predictive Biomarkers ◽  
Disease Outcomes ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Robust Measures

AbstractBackground & AimsInflammatory bowel diseases (IBD) are chronic inflammatory disorders where predictive biomarkers for the disease development and clinical course are sorely needed for development of prevention and early intervention strategies that can be implemented to improve clinical outcomes. Since gut microbiome alterations can reflect and/or contribute to impending host health changes, we examined whether gut microbiota metagenomic profiles would provide more robust measures for predicting disease outcomes in colitis-prone hosts.MethodsUsing the IL-10 gene-deficient (IL-10 KO) murine model where early life dysbiosis from antibiotic (cefoperozone, CPZ) treated dams vertically-transferred to pups increases risk for colitis later in life, we investigated temporal metagenomic profiles in the gut microbiota of post-weaning offspring and determined their relationship to eventual clinical outcomes.ResultsCompared to controls, offspring acquiring maternal CPZ-induced dysbiosis exhibited a restructuring of intestinal microbial membership both in bacteriome and mycobiome that were associated with alterations in specific functional subsystems. Furthermore, among IL-10 KO offspring from CPZ-treated dams, several functional subsystems, particularly nitrogen metabolism, diverged between mice that developed spontaneous colitis (CPZ-colitis) versus those that did not (CPZ-no-colitis) at a time point prior to eventual clinical outcome.ConclusionsOur findings provide support that functional metagenomic profiling of gut microbes has potential and promise meriting further study for development of tools to assess risk and manage human IBD.SynopsisCurrently, predictive markers for the development and course of inflammatory bowel diseases (IBD) are not available. This study supports the notion that gut microbiome metagenomic profiles could be developed into a useful tool to assess risk and manage human IBD.

FUT2 deficiency may influence the pathogenesis of inflammatory bowel diseases through gut microbiome

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Sijing Cheng ◽  
Jun Hu ◽  
Xianrui Wu ◽  
Na Jiao ◽  
Yichen Li ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Bowel Diseases ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document